Contrary to the idea that a pan-RAS inhibitor is superior, Varistem suggests a more targeted approach. Patients should first receive an inhibitor specific to their mutation (e.g., G12D). If resistance develops via a new RAS mutation, then a broader pan-RAS inhibitor should be used, creating a more rational, sequential treatment paradigm.
After a first-in-class drug proves a therapeutic approach works, the competitive landscape shifts. Second-generation drugs cannot just offer marginal efficacy gains. Instead, they must provide a significantly better quality of life and tolerability profile, as patients will be living with the side effects for longer periods of extended survival.
Some RAS inhibitors work by converting the "on" (active) state to the "off" (inactive) state, but they can only bind to the "on" state. Varistem's drug targets both states. This prevents the newly-formed "off" state protein from becoming re-activated and driving cancer signaling, a potential mechanism of resistance to "on-only" binders.
The dense stromal tissue surrounding pancreatic tumors acts as a physical barrier, protecting cancer cells from chemotherapy and immune cells. Varistem's FAK inhibitor, defactinib, targets this microenvironment by reducing fibroblasts and collagen. This "softens up" the tumor, allowing T-cells and other therapeutic agents to penetrate and attack the cancer more effectively.
Despite political pressure to decouple from China, Varistem's CEO defends their collaboration with Chinese firm Genfleet. He argues that leveraging global expertise is essential for bringing drugs to patients faster. The primary mission is to fight cancer, a global problem, which requires prioritizing scientific synergy and patient outcomes over nationalistic concerns and artificial barriers.
The CEO, motivated by personal loss, states that the current one-year survival gain from new RAS inhibitors is not enough. The true path to long-term survival lies in developing intelligent combinations. Varistem is even planning to combine its specific G12D inhibitor with a competitor's pan-RAS inhibitor to tackle resistance and improve durability for patients.